TrialJournal of immunotherapy (Hagerstown, Md. : 1997)
Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma.
René J Tavera et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
32 papers cite it
cites it